RGEN
Price
$145.13
Change
+$3.73 (+2.64%)
Updated
Apr 24, 04:59 PM (EDT)
Capitalization
10.26B
5 days until earnings call
STXS
Price
$2.02
Change
+$0.08 (+4.10%)
Updated
Apr 24, 04:59 PM (EDT)
Capitalization
214.36M
19 days until earnings call
Ad is loading...

RGEN vs STXS

Header iconRGEN vs STXS Comparison
Open Charts RGEN vs STXSBanner chart's image
Repligen
Price$145.13
Change+$3.73 (+2.64%)
Volume$5.14K
Capitalization10.26B
Stereotaxis
Price$2.02
Change+$0.08 (+4.10%)
Volume$2.02K
Capitalization214.36M
RGEN vs STXS Comparison Chart
Loading...
RGEN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
STXS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
RGEN vs. STXS commentary
Apr 25, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is RGEN is a Buy and STXS is a Hold.

Ad is loading...
COMPARISON
Comparison
Apr 25, 2025
Stock price -- (RGEN: $141.40 vs. STXS: $1.95)
Brand notoriety: RGEN and STXS are both not notable
Both companies represent the Medical Specialties industry
Current volume relative to the 65-day Moving Average: RGEN: 71% vs. STXS: 44%
Market capitalization -- RGEN: $10.26B vs. STXS: $214.36M
RGEN [@Medical Specialties] is valued at $10.26B. STXS’s [@Medical Specialties] market capitalization is $214.36M. The market cap for tickers in the [@Medical Specialties] industry ranges from $3.82T to $0. The average market capitalization across the [@Medical Specialties] industry is $8.31B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

RGEN’s FA Score shows that 1 FA rating(s) are green whileSTXS’s FA Score has 0 green FA rating(s).

  • RGEN’s FA Score: 1 green, 4 red.
  • STXS’s FA Score: 0 green, 5 red.
According to our system of comparison, RGEN is a better buy in the long-term than STXS.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

RGEN’s TA Score shows that 5 TA indicator(s) are bullish while STXS’s TA Score has 4 bullish TA indicator(s).

  • RGEN’s TA Score: 5 bullish, 4 bearish.
  • STXS’s TA Score: 4 bullish, 5 bearish.
According to our system of comparison, RGEN is a better buy in the short-term than STXS.

Price Growth

RGEN (@Medical Specialties) experienced а +7.04% price change this week, while STXS (@Medical Specialties) price change was +8.94% for the same time period.

The average weekly price growth across all stocks in the @Medical Specialties industry was +4.26%. For the same industry, the average monthly price growth was -6.64%, and the average quarterly price growth was -2.53%.

Reported Earning Dates

RGEN is expected to report earnings on Aug 05, 2025.

STXS is expected to report earnings on Aug 07, 2025.

Industries' Descriptions

@Medical Specialties (+4.26% weekly)

Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
RGEN($10.3B) has a higher market cap than STXS($214M). RGEN YTD gains are higher at: -1.765 vs. STXS (-14.474). RGEN has higher annual earnings (EBITDA): 134M vs. STXS (-21.24M). RGEN has more cash in the bank: 751M vs. STXS (19.8M). STXS has less debt than RGEN: STXS (5.49M) vs RGEN (712M). RGEN has higher revenues than STXS: RGEN (639M) vs STXS (26.8M).
RGENSTXSRGEN / STXS
Capitalization10.3B214M4,813%
EBITDA134M-21.24M-631%
Gain YTD-1.765-14.47412%
P/E Ratio247.52N/A-
Revenue639M26.8M2,384%
Total Cash751M19.8M3,793%
Total Debt712M5.49M12,969%
FUNDAMENTALS RATINGS
RGEN vs STXS: Fundamental Ratings
RGEN
STXS
OUTLOOK RATING
1..100
1225
VALUATION
overvalued / fair valued / undervalued
1..100
95
Overvalued
92
Overvalued
PROFIT vs RISK RATING
1..100
76100
SMR RATING
1..100
9098
PRICE GROWTH RATING
1..100
5855
P/E GROWTH RATING
1..100
251
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

STXS's Valuation (92) in the Medical Specialties industry is in the same range as RGEN (95) in the Biotechnology industry. This means that STXS’s stock grew similarly to RGEN’s over the last 12 months.

RGEN's Profit vs Risk Rating (76) in the Biotechnology industry is in the same range as STXS (100) in the Medical Specialties industry. This means that RGEN’s stock grew similarly to STXS’s over the last 12 months.

RGEN's SMR Rating (90) in the Biotechnology industry is in the same range as STXS (98) in the Medical Specialties industry. This means that RGEN’s stock grew similarly to STXS’s over the last 12 months.

STXS's Price Growth Rating (55) in the Medical Specialties industry is in the same range as RGEN (58) in the Biotechnology industry. This means that STXS’s stock grew similarly to RGEN’s over the last 12 months.

RGEN's P/E Growth Rating (2) in the Biotechnology industry is somewhat better than the same rating for STXS (51) in the Medical Specialties industry. This means that RGEN’s stock grew somewhat faster than STXS’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
RGENSTXS
RSI
ODDS (%)
Bullish Trend 2 days ago
90%
N/A
Stochastic
ODDS (%)
Bearish Trend 2 days ago
72%
Bearish Trend 2 days ago
88%
Momentum
ODDS (%)
Bullish Trend 2 days ago
71%
Bullish Trend 2 days ago
86%
MACD
ODDS (%)
Bullish Trend 2 days ago
76%
Bullish Trend 2 days ago
89%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
75%
Bullish Trend 2 days ago
82%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
73%
Bullish Trend 2 days ago
81%
Advances
ODDS (%)
Bullish Trend 2 days ago
75%
Bullish Trend 8 days ago
76%
Declines
ODDS (%)
Bearish Trend 21 days ago
79%
Bearish Trend 21 days ago
82%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
67%
Bearish Trend 2 days ago
90%
Aroon
ODDS (%)
Bearish Trend 2 days ago
77%
Bearish Trend 2 days ago
80%
View a ticker or compare two or three
Ad is loading...
RGEN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
STXS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
MVV51.831.25
+2.47%
ProShares Ultra MidCap400
BRNY38.600.80
+2.10%
Burney U.S. Factor Rotation ETF
ROAM23.400.15
+0.65%
Hartford Multifactor Emerging Mkts ETF
USMV90.370.34
+0.38%
iShares MSCI USA Min Vol Factor ETF
FREL26.320.05
+0.19%
Fidelity MSCI Real Estate ETF